Novo Nordisk's Buyback Engine Keeps Running as Pipeline Deals and FDA Timelines Set the Pace

Novo Nordisk leans on DKK 15 billion buybacks and a $2.6 billion Hengrui licensing deal as shares fall 25% this year and Denecimig review slips.

Novo Nordisk is leaning on two familiar levers to defend its growth story: a steady stream of share repurchases and a pipeline strategy that mixes in-house science with outside bets. The dual approach comes as the Danish drugmaker's stock continues to search for footing — it closed Friday at EUR 33.06, down 25% since the start of the year.

The company disclosed on September 28 the purchase of 1,205,000 B-shares over a single trading week, part of a broader program worth up to DKK 15 billion. Those ongoing buybacks offer support in a period of mounting competitive pressure, while also signaling management's confidence in medium- and long-term earnings power. Operational hurdles on individual development fronts, however, are testing investors' patience.

A Regulatory Hiccup and a Chinese Licensing Play

Among those hurdles is the regulatory review of Denecimig for hemophilia A. The U.S. Food and Drug Administration is extending its assessment because remediation work is underway at a manufacturing site. The agency did not set a new decision date, though it raised no concerns about clinical efficacy or the safety data submitted. Novo Nordisk said the delay does not affect its 2026 financial outlook and still targets a U.S. launch in the first half of 2027, subject to approval.

In parallel, the group is widening its obesity portfolio. Roughly a week ago — with the stock down 2.1% since — Novo Nordisk secured licensing rights to the experimental candidate HRS-1596 from Jiangsu Hengrui Pharmaceuticals for territories outside mainland China, Hong Kong, Macau and Taiwan. According to Reuters, the total financial package, including an upfront payment, reaches up to $2.6 billion for the planned weight-loss pill. The transaction is expected to close in the fourth quarter of 2026, pending antitrust clearance in the United States.

Clinical Data Bolster the Obesity Franchise

New study results are reinforcing the case for the company's development candidates. At the EASD conference, Novo Nordisk presented data on the CagriSema combination documenting altered brain responses to calorie-rich food as well as effects on organ fat and bone health. In the Phase 3 REIMAGINE 5 trial involving adults with type 2 diabetes, the drug previously achieved an estimated average weight loss of 12.4%, compared with 9.1% for tirzepatide. The REDEFINE 9 study showed a 21% reduction in body weight versus placebo. Additional findings suggest the treatment can curb food cravings and reduce organ fat.

For Wegovy, further clinical insights have emerged as well. A subgroup analysis of the STEP-UP trial covering 55 adults with obesity and excess liver fat showed clear effects after 72 weeks: the active ingredient reduced liver fat to normal levels in nine out of ten participants.

A Capital Markets Day That Failed to Reassure

Sentiment on the stock has been under strain for weeks. About two weeks ago, a capital markets day left investors underwhelmed, and the shares have lost 5.1% since, at one point dropping as much as 9%. Reuters reported that the long-term targets did little to ease concerns about near-term growth. Discussion centered on how the company intends to sustain growth ahead of looming patent expirations. Management reaffirmed plans to massively expand capacity for oral formulations and reach significantly more patients worldwide, while noting that the 2030 targets are strategic ambitions rather than a financial forecast.

On September 22, research firm CFRA downgraded Novo Nordisk's U.S. depositary receipts from Hold to Sell, setting a price target of $38. The analysts cited an unfavorable risk-reward profile during a transition phase after peak profits for GLP-1 drugs, along with intensifying competition.

Partnerships as a Bridge Past the Patent Cliff

To counter such risks, the company is betting on partnerships and the expansion of early-stage candidates, bringing new molecules on board early to defend its long-term position in metabolic diseases. Patent expirations are drawing closer and rivals are closing the gap. While Novo Nordisk has reaffirmed its ability to develop new blockbusters, many investors remain cautious about the period after the current obesity-drug boom, focusing on future pricing power and the pace of new therapies.

The picture for shareholders is a mixed one: manufacturing questions are delaying specialized applications, while research in the obesity segment is strengthening the strategic foundation. What market participants appear to want most is reliable operational execution of the growth plan.